Richard Davies

Senior Advisor

Richard Davies joined the Advisory Board of CellResearch Corporation as Senior Advisor in the middle of 2018. Richard brings over 27 years’ of experience in the global healthcare industry in roles that spanned business development, commercialisation and sales, invaluable assets in this growth phase of CellResearch.

Richard is currently Chairman of the Board at Alvotech, a pioneering biosimilars Company. He has previously served on the Boards of ZHOPL and Medicines Australia. Richard was most recently chief executive officer of BONESUPPORT AB where he successfully led the growth of the company through its initial public offering after gaining approval for a pivotal clinical study design with the FDA. Prior to this, he was chief commercial officer of Hospira for 4 years, where he was responsible for continued revenue growth of 12% per year, after which the company was acquired by Pfizer for $15 billion. For a decade before joining Hospira, Richard served in several leadership roles at Amgen Inc. where he oversaw the biotechnology company’s business expansion into Central and Eastern Europe, Australia, Asia and Latin America. Prior to Amgen, Richard held roles of increasing seniority at Eli Lilly for 13 years.